SLIDE 1
AI Longevity Consortium at King’s College London
The UK’s First Dedicated AI for Longevity Hub: Agenda for 2020 and Beyond
SLIDE 2 Longevity AI Consortium Overview
◆ The Longevity AI Consortium serves as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and
- therapeutics. The main concept of precision medicine is providing health care which is
individually tailored on the basis of a person’s genes, lifestyle and environment. ◆ The Consortium will develop a comprehensive cloud computing platform to enable the development of “minimum viable” and “most comprehensive” panels of biomarkers of ageing, creating an ecosystem that incentivizes the participation of doctors, clinics, data providers, AI companies and corporate partners, and which enables efficient and streamlined commercialization and clinical implementation of both validated and experimental biomarkers of ageing as a framework for the extension of national Healthy Longevity in the UK.
SLIDE 3 Our Team and Advisors
- Dr. Richard Siow
- Dr. Alex
Zhavoronkov Dmitry Kaminskiy Eric Kihlstrom Director at Ageing Research at King's (ARK) Chief Scientific Officer / AI Biomarkers of Ageing Managing Trustee at Biogerontology Research Foundation / Strategic Advisor
Intelligence and Commercialisation Director at Aging Analytics Agency / Former Interim Director of the £98 million Healthy Ageing Industrial Strategy Challenge Fund
SLIDE 4
Strategic Partners and Sponsors
Aging Analytics Agency Biogerontology Research Foundation Longevity International Insilico Medicine Deep Knowledge Ventures
SLIDE 5 Longevity AI Consortium Investment Model
Partners’ Network Core Capabilities Values and Importance
2020 launching a new decade
Longevity R&D A comprehensive cloud computing platform to enable the development of “minimum viable” and “most comprehensive” panels of biomarkers of ageing A synergetic and efficient infrastructure spanning both industry, academia and the venture capital sector Global network of experts in the areas of scientific R&D, business development and investment relations. Leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics.
SLIDE 6 Main Definitions
◆ Artificial Intelligence is the application of rapid data processing, machine learning, predictive analysis, and automation to simulate intelligent behavior and problem solving capabilities with machines and software. These processes include learning (the acquisition of information and rules for using the information), reasoning (using rules to reach approximate or definite conclusions) and self-correction. ◆ Longevity is defined as the number of years as a person could expect to live free from chronic age-related diseases and non-productivity if he or she were to pass through life subject to the age-specific mortality rates for a given period. Longevity specifically refers to the balance between the length of time someone lives and the quality of life in terms
- f the absence of disease.
SLIDE 7 Artificial Intelligence Technology Landscape
AI
Autonomous Systems Machine Learning Pattern Recognition Natural Language Processing Neural Networks Chatbots Real Time Emotion Analytics Thought Controlled Gaming Real Time Universal Translation Virtual Companions Next Gen Cloud Robotics Autonomous Surgical Robotics Robotic Personal Assistance Robotic Cyber Security Neuromorphic Computing Deep Learning
SLIDE 8 Longevity Industry Framework
P4 MEDICINE Personalized Diagnostics Personalized QALY & HALE Estimation Personalized Biomarker Analysis Personalized Prognostics Preventive Therapies
Personalized in vivo & in silico drug testing
AGETECH Cognitive Enhancement NextGen Mobile Apps for the Elderly Entertainment for the Elderly Novel Retirement Plans Continuing Education FinTech for the Elderly NOVEL FINANCIAL SYSTEM Longevity Hedge Fund AgeTech Bank Longevity Index Fund Longevity Derivatives Longevity Stock Exchange Longevity Trust GEROSCIENCE R&D Gene Therapy Regenerative Medicine Basic Research on Biology of Aging Rejuvenation Biotechnology Nutraceuticals Geroprotectors
SLIDE 9 Ageing Research at King’s College London: Partnerships
The Francis Crick Institute is the new national institute for biomedical research focusing on new ways to diagnose, treat and prevent diseases. King's Health Partners is an Academic Health Science Centre where world-class research, education and clinical practice are brought together for the benefit of patients. The Healthy Ageing clinical theme at the Health Innovation Network is primarily concerned with the promotion of healthy living and the prevention and management of illness and disability affecting older people.
SLIDE 10 Ageing Research at King’s College London: Partnerships
The PLuS Alliance combines the strengths
universities Arizona State University, King’s College London and University of New South Wales Sydney to contribute to a more just and sustainable future. The ARK-TransCampus partnership aims to stimulate, support and enable collaborations in fields of research within the ageing themes through academic exchange and sharing of resources to promote knowledge transfer. Science Gallery London connects art, science and health to drive innovation in the heart of the city. Science Gallery London is part of the Global Science Gallery Network, connecting King’s researchers to galleries worldwide.
SLIDE 11 Industry
The Longevity AI Consortium serves as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and
- therapeutics. The main concept of
precision medicine is providing health care which is individually tailored on the basis of a person’s genes, lifestyle and
- environment. With the advances in
genetics, artificial intelligence and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality.
Cross-Sector Synergy Leveraging Unique Synergies in Academia, Industry and Finance
Academia Finance / VC
SLIDE 12 Artificial Intelligence: the Game Changer for Precision Health and Longevity
Longevity Precision Health Financial Wellness
AI for Longevity Development of Biomarkers of Ageing AI for WealthTech and AgeTech AI for Longevity Clinical Trials AI for Continuous Biomarker Monitoring AI for Longevity R&D Novel Uses of Life and Health Data Third-Party Ecosystem Participants
SLIDE 13 Primary R&D Goals for 2020 - End-to-End Healthy Longevity Research
Identification of novel longevity and healthy ageing biomarkers Accelerated diagnosis of age-related health decline, with increased accuracy Refining demographic and clinical methods to facilitate recruitment, retention Development of personalised health, longevity and treatment practices Longevity-focused modulation
- f sleep, nutrition, physical
activity and environmental exposure Developing AI-empowered solutions for financial wellness across extended periods of healthy longevity
Major R&D Focus and Goals for 2020
SLIDE 14 Core Areas of R&D: Full Scope Research Across Biomedicine, Tech and Finance Longevity AI Consortium
R&D on AI for mental health to optimize psychological wellness, social activity, combat loneliness and social isolation among elderly. A paradigm shift from treatment to prevention and a new frontier - from precision medicine to precision health Precision Health: AI-Driven Advanced Prognostics, Personalised Treatment Optimization, and AI-Driven Preventative Treatment. Niches where the science is ahead of the funding: microbiome diagnostics and therapeutics, recent innovations in advanced cosmetics. Longevity clinical data, a comprehensive cloud computing platform, which enables efficient and streamlined commercialization and clinical implementation of both validated and experimental biomarkers of ageing. R&D on AI for Financial Wellness to maintain financial stability, social activity and psychological well-being across extended periods of Healthy Longevity.
SLIDE 15 Accelerator Program: Supporting External Startups
Spin Outs: Turning Research into Products Advanced AI for Longevity R&D
Bridging Advanced R&D with Commercialization and Practical Implementation
Bridging Research with Rapid Practical Implementation
SLIDE 16 Building an Ecosystem for Academic - Industry - Public-Sector Synergy
AI Center for Longevity AI Medical Centers AI Center for Financial Wellness
UK AI Center Trifecta Development of Biomarkers of Ageing Corporate Partners Corporate Partners Doctors and Clinics AI Companies NHS-X Third-Party Ecosystem Participants
SLIDE 17 Priority Areas of the Longevity AI Consortium
Frontier applications of artificial intelligence in ageing research, longevity R&D and the development of actionable biomarkers of health, ageing and longevity. The increasing shift toward actionable biomarkers
- f ageing, including the identification of
biomarkers of health and longevity and that have the highest ratios of accuracy and precision vs. actionability, expense and ease-of-implementation, and the benchmarking of biomarkers that can be used in practice today to test the effectiveness of longevity therapeutics and lifestyle interventions.
SLIDE 18 2019
20% 80%
2025
Treatment of Chronic and Last Stage Diseases Deep Diagnostics and Preventive Medicine Precision Preventive Personalized Medicine Treatment of Chronic and Last Stage Diseases
50% 50%
One-Size-Fit-All Biomarkers Personal Profile of Complex Biomarkers Networks Patients Grouping Individual Patient Level Data Science and AI application leading to the Biomarker discovery and implementation
18 Aging Analytics Agency
Paradigm Shift from Treatment to Prevention
SLIDE 19 Priority Areas of the Longevity AI Consortium
The paradigm shift treatment to prevention medicine, and from preventive medicine to precision health, utilizing nearly real-time assessment of biomarkers of ageing to coordinate micro-dose interventions to continually rebalance biomarkers of health and longevity and maintain an optimal state
- f precision health, and how AI will be
necessary for the coordination of biomarker monitoring and interventions due to the sheer volume of data. Novel uses of AI in Longevity drug design and development and clinical trial management.
SLIDE 20 AI-Driven Development of Biomarker Panels of Aging
Biomarker panel
2019 2020 2021
Timeline
Marker 1 Marker 2 Marker 3 Marker 4 Marker 5 Marker 6 Marker 7 Marker 8 Marker 9 Marker 10 Marker 11 Marker 12 Marker 13 Marker 14 Marker 15 Marker 16 Marker 17 Marker 18 Marker 19 Marker 1 Marker 2 Marker 3 Marker 4 Marker 5 Marker 6 Marker 7 Marker 8 Marker 9 Marker 10 Marker 11 Marker 12 Marker 13 Marker 14 Marker 15 Marker 16 Marker 17 Marker 18 Marker 19
Unfulfilled Biomarkers Validated Biomarkers adopted in practice Experimental Biomarkers adopted in practice
Aging Analytics Agency
Artificial Intelligence will use Digital Biomarkers to reality-check the proposed longevity therapies and filter out inappropriate
impractical biomarkers from those effective.
20
SLIDE 21
The disruptive and accelerative impact that AI is having on Longevity R&D and the practical implementation and clinical translation of Longevity technologies and therapeutics. Emerging trends and novel paradigms relating to both the creation and application of life data collected on a massive scale from healthy individuals and used in scientifically-backed, quantifiable, tangible and precise ways to preserve and maintain an optimal state of health.
Priority Areas of the Longevity AI Consortium
SLIDE 22
AI for Precision Medicine
Precision Medicine Market Segments Omic R&D, Sequencing Data Aggregation Platforms Biomedical Informatics Genetic Test Interpretation Clinical Decision Support AI Analytics
SLIDE 23 Frontier applications of AI for psychological and financial wellness over extended periods of healthy Longevity, and the maintenance and
- ptimization of “wealthspan” to compliment
advances in “healthspan”, including the application of AI assistants and “robo-advisors” for personal financial management, and the utilization of novel forms of financial data to enable AI-empowered AgeTech and WealthTech services. Novel advances in utilizing AI to optimize psychological wellness, social activity, promote neuroplasticity and combat loneliness and social isolation among elderly.
Priority Areas of the Longevity AI Consortium
SLIDE 24 2025
Stabilized State of Health and Biological Age Optimized Function
50% 50%
2019
Deep Diagnostics Prevention of Pathologies at the Early Stage
50% 50%
P4 Medicine Precision Health
The New Frontier - from Precision Medicine to Precision Health
Data Science and AI application leading to the Biomarker discovery and implementation
24 Aging Analytics Agency
SLIDE 25
AI-Driven Precision Diagnostics AI-Driven Advanced Prognostics Personalised Treatment Optimization AI-Driven Preventative Treatment
Accelerating the Development of Precision Health through AI
SLIDE 26
AI for Financial Wellness
Financial services innovators have an opportunity to greatly enhance the financial lives of the aged 60+ aiming to Live up to 100 years individuals by designing new solutions, in addition to adapting existing products and services.
AI-empowered Wealth Tech Services Investing tools Robo-advisors Robo-retirement Micro-Investing Financial services software Digital brokerage
SLIDE 27
ARK - AI Centre for Longevity at King’s College London
SLIDE 28 AI Longevity Accelerator
AI Longevity Accelerator is the World’s First Specialised Accelerator, focused on the AI for Longevity Industry
“SPIN-OFF” COMPANIES “SPIN-IN” COMPANIES MENTORSHIP AND INCUBATION SCIENTIFIC PUBLICATIONS GROWTH VC INVESTMENTS AND GOVERNMENTAL GRANTS DIRECT ACCESS TO INDUSTRY EXPERTS IN-DEPTH INDUSTRY EXPERTISE SOPHISTICATED SCIENTIFIC VALIDATION
AI LONGEVITY ACCELERATOR
ADVANCED BENCHMARKING & INVESTMENT ANALYTICS DEEP MARKET INTELLIGENCE
SLIDE 29 STRICTLY CONFIDENTIAL
DEEP KNOWLEDGE GROUP GEOGRAPHY
SWITZERLAND UNITED STATES
UNITED KINGDOM
SINGAPORE ISRAEL
AI Longevity Accelerator Global Aspect
2024 2020
2019
2021 2022
JAPAN
2023
CHINA
2022
SLIDE 30 STRICTLY CONFIDENTIAL
DEEP KNOWLEDGE GROUP GEOGRAPHY
Funding by Deep Knowledge Group to the Longevity AI Consortium
Deep Knowledge Group is providing the Longevity AI Consortium with £2 million for non-profit activities over a 3-year period. Deep Knowledge Ventures will provide the Longevity AI Consortium with £5 million for commercial activities
The further liquidity and syndication of the investment rounds will be provided and supported by Longevity.Capital
SLIDE 31 AI Longevity Accelerator at King’s College London - Summary
◆ In 2020 the AI Longevity Consortium plans to launch an AI Longevity Accelerator Programme in partnership with Deep Knowledge Ventures and Ageing Research at King’s that will serve as a much-needed bridge between startups focusing on AI for Longevity research and drug development and major UK investors. ◆ A cooperative, synergetic and efficient infrastructure spanning both industry, academia and the venture capital sector needs to be developed to promote increased investments and developments in this sector. ◆ All startups selected for inclusion into the accelerator will also receive mentorship and incubation resources, and will gain access to our global network of experts in the areas
- f scientific R&D, business development and investment relations.
SLIDE 32
CONTACT US
info@ai-longevity.center www.ai-longevity.center
